Inhibitory effect of erythromycin on potassium currents in rat ventricular myocytes in comparison with disopyramide
Authors:
- 1 July 2003
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 55 (7) , 995-1002
Abstract
Disopyramide, a class la antiarrhythmic agent, has been reported to induce torsades de pointes (TdP) associated with excessive QT prolongation in electrocardiogram (ECG), especially when concomitantly administered with erythromycin, a macrolide antibiotic agent. In this study, we have evaluated the effects of erythromycin on action potential duration (APD) and potassium currents in rat ventricular myocytes in comparison with disopyramide. We have evaluated the relationship between in-vitro potassium current inhibition and in-vivo QT prolongation observed in a previous study. Action potentials and membrane potassium currents, including delayed rectifier current (IK) and transient outward current (Ito), were recorded using a whole-cell patch clamp method in enzymatically-dissociated ventricular cells. Erythromycin and disopyramide prolonged APD in a concentration-dependent manner. Disopyramide (10–100 μm) and erythromycin (100 μm) led to increases in the APD at 90% repolarization level. Disopyramide reduced IK (IC50 = 37.2 + 0.17 μm) and Ito (IC50 = 20.9 + 0.13 μm) while erythromycin reduced IK (IC50 = 60.1 + 0.29 μm) but not Ito. The observed prolongation of APD might be ascribed to the inhibition of potassium currents. Erythromycin produced the prolongation of APD and the inhibition of potassium currents with a lag time after addition of the drugs, which suggested that erythromycin might not reach potassium channels from outside the ventricular cells. The potency of disopyramide was almost equivalent under in-vitro and in-vivo conditions. However, potency of erythromycin in-vitro was far weaker than that in-vivo reported in a previous study, presumably due to a difference in the uptake of erythromycin into ventricular myocytes between in-vivo and in-vitro conditions. Therefore, when drug-induced risks of QT prolongation are to be evaluated, the difference of potencies between in-vitro and in-vivo should be taken into consideration.Keywords
This publication has 21 references indexed in Scilit:
- Four different components contribute to outward current in rat ventricular myocytesAmerican Journal of Physiology-Heart and Circulatory Physiology, 1999
- Pharmacodynamic analysis of the electrocardiographic interaction between disopyramide and erythromycin in ratsJournal of Pharmaceutical Sciences, 1999
- Cellular and Ionic Mechanisms Underlying Erythromycin-Induced Long QT Intervals and Torsade de PointesJACC, 1996
- High- and Low-Affinity Sites for [3H]Dofetilide Binding to Guinea Pig MyocytesCirculation Research, 1995
- Erythromycin Blocks the Rapid Component of the Delayed Rectifier Potassium Current and Lengthens Repolarization of Guinea Pig Ventricular MyocytesCirculation, 1995
- Erythromycin-Induced QT Prolongation and Polymorphic Ventricular Tachycardia (Torsades de Pointes): Case Report and ReviewClinical Infectious Diseases, 1994
- Torsades de Pointes Induced by ErythromycinChest, 1994
- New observations on the mechanisms of antiarrhythmic actions of disopyramide on cardiac membranesThe American Journal of Cardiology, 1989
- Comparative effects of three class I antiarrhythmic drugs on plateau and pacemaker currents of sheep cardiac Purkinje fibresCardiovascular Research, 1988
- Kinetics of onset of rate-dependent effects of Class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassificationCardiovascular Research, 1983